Affilogic is a private biotech company specialized in discovering and developing Nanofitins^® through early-stage collaborations with worldwide industry leaders in the pharmaceutical sector.

These affinity proteins can be designed as targeted inhibitors, or as vectors for specific addressing of cells and tissues. Affilogic follows the science to any therapeutic area as long as an innovative Nanofitin-based biotherapy can make a difference to meet patients’ needs. Usual systemic routes can be travelled by Nanofitins^®, but their intrinsic properties make them amenable to other routes, such as oral route and pulmonary delivery.